Pharmacologic Inhibition of Vacuolar H+ATPase Attenuates Features of Severe Asthma in Mice

What is it about?

Severe asthma is relatively uncommon and generally affects 10-15% of people with asthma. The high utilization and cost of severe asthma is in disproportion to its frequency among persistent asthmatics but there is no effective medicine to treat severe asthma therefore presents a clear unmet medical need to identify and discover new drugs. In here, we present the preclinical efficacy of Bafilomycin a V-ATPase inhibitor in a murine model of severe asthma.

Featured Image